"Gencurix will disclose two colorectal cancer clinical research results using its self-developed molecular diagnostic test method at the 2024 American Society of Clinical Oncology (ASCO) annual conference held on May 31."
8 months ago
Clinical data
|
COLO eDX • Droplex BRAF Mutation Test • Droplex KRAS Mutation Test
"Six types of Gencurix' companion diagnostic tests (Droplex) have been approved for sale in Turkiye, covering most of the Droplex test portfolio in Romania, Colombia, and Germany."
1 year ago
Non-US regulatory
|
Droplex BRAF Mutation Test • Droplex EGFR Mutation Test v2 • Droplex KRAS Mutation Test • Droplex PIK3CA Mutation Test • Droplex POLE Mutation Test • Droplex c-Met Exon14 Skipping Test
"Gencurix announced...that it had signed a local agency supply contract with German Biotype...Gencurix plans to supply the Dropplex diagnostic kit, a digital PCR-based cancer companion diagnostic product, to Germany and other European countries through Biotype. Gencurix received European in vitro diagnostic medical device certification (CE-IVD) for six Dropplex products."
over 1 year ago
Licensing / partnership
|
Droplex BRAF Mutation Test • Droplex EGFR Mutation Test v2 • Droplex KRAS Mutation Test • Droplex PIK3CA Mutation Test • Droplex POLE Mutation Test • Droplex c-Met Exon14 Skipping Test
"Gencurix announced on the 8th that it has received manufacturing and product approval for the 'Droplex BRAF Mutation Test', a thyroid cancer mutation test, from the Ministry of Food and Drug Safety...This product tests the presence of mutations in the 'BRAF' gene 'Codon600(V600E)', which occurs most commonly in thyroid cancer patients, using digital gene amplification (PCR) method. The V600E mutation accounts for more than 98% of BRAF mutations."
"Gencurix...announced on the 21st that it has obtained European certification (CE) for 6 types of 'Dropplex', a molecular diagnostic (PCR)-based cancer companion diagnostic product...Dropplex consists of products that target a total of six biomarkers (biomarkers) including lung cancer (EGFR v2, c-MET), colorectal cancer (KRAS), endometrial cancer (POLE), breast cancer (PIK3CA) and thyroid cancer (BRAF)."
over 2 years ago
European regulatory
|
Droplex BRAF Mutation Test • Droplex EGFR Mutation Test v2 • Droplex KRAS Mutation Test • Droplex PIK3CA Mutation Test • Droplex POLE Mutation Test • Droplex c-Met Exon14 Skipping Test